WallStreetZenWallStreetZen

NASDAQ: MGNX
Macrogenics Inc Stock

$5.02+0.16 (+3.29%)
Updated Jun 5, 2023
MGNX Price
$5.02
Fair Value Price
$6.79
Market Cap
$310.43M
52 Week Low
$2.13
52 Week High
$7.90
P/E
-3.41x
P/B
2.84x
P/S
2.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$165.34M
Earnings
-$91.32M
Gross Margin
93.4%
Operating Margin
-54.84%
Profit Margin
-55.2%
Debt to Equity
2.14
Operating Cash Flow
-$42M
Beta
1.21
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

MGNX Overview

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MGNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

MGNX ($5.02) is undervalued by 26.09% relative to our estimate of its Fair Value price of $6.79 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
MGNX ($5.02) is significantly undervalued by 26.09% relative to our estimate of its Fair Value price of $6.79 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
MGNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MGNX due diligence checks available for Premium users.

Be the first to know about important MGNX news, forecast changes, insider trades & much more!

MGNX News

Valuation

MGNX fair value

Fair Value of MGNX stock based on Discounted Cash Flow (DCF)
Price
$5.02
Fair Value
$6.79
Undervalued by
26.09%
MGNX ($5.02) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MGNX ($5.02) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MGNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

MGNX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-3.41x
Industry
11.59x
Market
53.21x

MGNX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
2.84x
Industry
5.21x
MGNX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

MGNX's financial health

Profit margin

Revenue
$24.5M
Net Income
-$38.0M
Profit Margin
-155.2%
MGNX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MGNX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$343.5M
Liabilities
$234.2M
Debt to equity
2.14
MGNX's short-term assets ($288.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGNX's short-term assets ($288.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGNX's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
MGNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$12.8M
Investing
$28.1M
Financing
$100.1M
MGNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

MGNX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
MGNX$310.43M+3.29%-3.41x2.84x
DSGN$308.26M-4.34%-4.41x0.99x
FHTX$304.07M+2.39%-2.69x-12.37x
ATAI$302.14M+3.41%-1.90x1.28x
STRO$301.48M+5.72%-2.10x1.63x

Macrogenics Stock FAQ

What is Macrogenics's quote symbol?

(NASDAQ: MGNX) Macrogenics trades on the NASDAQ under the ticker symbol MGNX. Macrogenics stock quotes can also be displayed as NASDAQ: MGNX.

If you're new to stock investing, here's how to buy Macrogenics stock.

What is the 52 week high and low for Macrogenics (NASDAQ: MGNX)?

(NASDAQ: MGNX) Macrogenics's 52-week high was $7.90, and its 52-week low was $2.13. It is currently -36.46% from its 52-week high and 135.68% from its 52-week low.

How much is Macrogenics stock worth today?

(NASDAQ: MGNX) Macrogenics currently has 61,838,893 outstanding shares. With Macrogenics stock trading at $5.02 per share, the total value of Macrogenics stock (market capitalization) is $310.43M.

Macrogenics stock was originally listed at a price of $24.99 in Oct 10, 2013. If you had invested in Macrogenics stock at $24.99, your return over the last 9 years would have been -79.91%, for an annualized return of -16.33% (not including any dividends or dividend reinvestments).

How much is Macrogenics's stock price per share?

(NASDAQ: MGNX) Macrogenics stock price per share is $5.02 today (as of Jun 5, 2023).

What is Macrogenics's Market Cap?

(NASDAQ: MGNX) Macrogenics's market cap is $310.43M, as of Jun 6, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Macrogenics's market cap is calculated by multiplying MGNX's current stock price of $5.02 by MGNX's total outstanding shares of 61,838,893.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.